AARTIDRUGS / NSE / Biotechnology & Drugs
Aarti Drugs
1Y Price Trend
Key Information
Recommendations
RatingHold
Target High574.95
Target Low318.6
Target Mean3
Target Median50
Risk Metrics
Overall RiskBalanced risk
Board Risk31.42
Key Analysis
Overall score, performance score, return rating, defensive, aggressive, and balanced views.
Download appProjection Analytics
Best-case, base-case, worst-case, and dynamic AI projection views.
Download appLatest stock news
Aarti Drugs to hold virtual investor meeting on June 10 scanx.trade
Aarti Drugs Ltd Downgraded to Sell Amid Mixed Financial and Valuation Signals Markets Mojo
Aarti Drugs Ltd Downgraded to Strong Sell Amid Weak Financials and Bearish Technicals Markets Mojo
Aarti Drugs Ltd is Rated Sell by MarketsMOJO Markets Mojo
Aarti Drugs Q4 PAT Rises 36% QoQ to INR55.3 Crores scanx.trade
Aarti Drugs Publishes Q4 FY26 Earnings Call Transcript for Investors TipRanks
Aarti Drugs Posts 12% Profit Drop in Q4 FY26 Despite Revenue Growth Whalesbook
Aarti Drugs Limited Q4 FY26 Results Highlight Operational Scale-Up and Recovery InvestyWise
© SharekeyX | Rusaka Technologies 2024-2026

